Biotech firm Windtree Therapeutics announced plans to purchase up to $700 million in BNB, following the cryptocurrency's recent all-time high. The Nasdaq-listed company aims to enhance its balance sheet with the investment, which includes raising $520 million through an equity line of credit and a $20 million stock-purchase agreement. This initiative is part of a broader trend of publicly traded companies acquiring digital assets. The CEO, Jed Latkin, emphasized the importance of securing additional funds for BNB purchases, which could strengthen stockholder confidence. Currently, BNB holds a market cap of $106.9 billion, reflecting its position as the fifth-largest digital coin. Windtree's stock witnessed a significant increase of 162% over the past month, despite a 5% drop on the announcement day. Other companies, such as Chinese firm Nano Labs, have also entered the crypto treasury market, further propelling interest in non-Bitcoin digital assets.

Source 🔗